Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 37
  1. Apr 07, 2026 · 09:18 · NRX · Material +

    “Strategic LOI with BioXtek could fast‑track U.S. exosome manufacturing and de‑risk clinical rollout”

    NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

    01
  2. Apr 07, 2026 · 08:18 · SONA · Routine +

    Preclinical combo of THT and PD‑1 shows durable tumor clearance, reinforcing pipeline momentum

    Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study

    02
  3. Apr 07, 2026 · 07:30 · NGEN · Material +

    FDA aligns on Phase 3 design, clearing the path for NVG‑291’s registrational trial

    NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

    03
  4. Apr 07, 2026 · 07:30 · MRVL · Routine +

    New strategic financing trims Phase I cash burn, nudging MB‑204 toward first‑in‑human trial

    Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures

    04
  5. Apr 07, 2026 · 07:03 · FRX · Routine +

    Fennec’s steady stream of real‑world data builds a foundation for label expansion – but near‑term catalysts remain incremental.

    Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

    05
  6. Apr 07, 2026 · 07:01 · TELY · Routine +

    Delivering essential medication with no friction, no delays, and no barriers

    TelyRx Holdings Inc. to Commence Trading on the Toronto Stock Exchange Effective April 7, 2026

    06
  7. Apr 07, 2026 · 07:01 · VIVI · Routine +

    Brazilian patent bolsters TempraMed’s IP moat ahead of VIVI Box launch.

    TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product

    07
  8. Apr 07, 2026 · 07:00 · BLCO · Routine +

    N/A

    Bausch + Lomb Launches Preloaded enVista Envy(TM) Full Range of Vision Intraocular Lenses in Europe

    08
  9. Apr 07, 2026 · 03:05 · BNXT · Routine +

    BioNxt secures unitary EU patent, advancing European commercialization of its sublingual cladribine ODF platform

    BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

    09
  10. Apr 06, 2026 · 06:52 · INNO · Routine +

    Innovating drug delivery for chronic pain solutions

    Innocan Pharma Announces Closing of Additional Debenture

    10
  11. Apr 04, 2026 · 20:26 · KETA

    Tripsitter Clinic to settle $292,311 shares with debt

    Tripsitter Clinic to settle $292,311 shares with debt

    11
  12. Apr 02, 2026 · 18:15 · BETR · Routine +

    Betterlife issues 2.15M shares in debenture conversion

    Betterlife issues 2.15M shares in debenture conversion

    12
  13. Apr 02, 2026 · 18:11 · QNTM · Material +

    Quantum Biopharma wins market manipulation lawsuit

    Quantum Biopharma wins market manipulation lawsuit

    13
  14. Apr 02, 2026 · 17:43 · SHRX · Routine +

    Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

    Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

    14
← Newer Older →